In this presentation you will learn about cutting-edge preclinical mouse platforms used to evaluate immuno-modulatory therapies for human cancer. Discussion topics include: Overview of Onco-Hu™ mice (tumor bearing Hu-NSG™ and Hu-NSG-SGM3™); Growth kinetics of patient derived tumors (PDX) in NSG™ vs. Hu-NSG™; Comparison of human immune reconstitution in NSG™ vs. NSG-SGM3™ mice; and, Therapeutic response to chemotherapy and an anti-PD1 check-point inhibitor in Onco-Hu™ mice
State, Province or Country: